According to Mylan, the deal will allow the new company to “meaningfully expand the geographic reach” of its portfolio and its future products, including its complex generics and its biosimilars, into markets where Upjohn has existing infrastructure.
Pfizer’s off-patent drug unit, Upjohn, and Mylan have announced a deal under which they will combine to form a new company that will have expanded reach.
If the proposed transaction—which is subject to a Mylan shareholder vote and regulatory approvals—closes, Pfizer’s shareholders will own 57%, and Mylan shareholders will own 43%, of the combined company. Mylan’s chief executive officer (CEO), Heather Bresch, will retire, effective of the date of the transaction’s closure, which is expected to fall in mid-2020. The new company’s CEO will be Michael Goettler, current group president of Upjohn.
In a statement, Pfizer CEO Albert Bourla, PhD, said that “I believe that Mylan’s unique profile and strategy has made it the obvious partner of choice in creating this powerful combination. By bringing Mylan’s growth assets to Upjohn’s growth markets, we will create a financially strong company with true global reach.” According to the companies, the new entity, which will be domiciled in the United States, is expected to bring in $19 billion to $20 billion in worldwide revenues in 2020.
According to Mylan, the deal will allow the new company to “meaningfully expand the geographic reach” of its portfolio and its future products, including its complex generics and its biosimilars, into markets where Upjohn has existing infrastructure. While Mylan has a strong footprint in the United States and Europe, Upjohn is already in Asia and emerging markets.
Among the products that Mylan notes as bringing growth potential to Upjohn are its trastuzumab biosimilar (Ogivri), its bevacizumab biosimilar (the India-approved and launched Abevmy), its pegfilgrastim biosimilar (Fulphila), and its insulin glargine biosimilar (Semglee, approved and launched in the European Union and elsewhere). The companies also point to a combined pipeline that will see the unit develop biosimilars of abatacept (referencing Orencia) and aflibercept (referencing Eylea).
In an email to The Center for Biosimilars®, a representative from Pfizer confirmed that Pfizer’s biosimilars are not a part of the proposed transaction, and that they will remain part of their own business unit within Pfizer.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.